Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2016

View Archived Issues

Aralez to acquire U.S. rights to Toprol-XL from AstraZeneca

Morphotek signs exclusive license agreement with Eurofarma Laboratiorios

English NICE recommends Tagrisso as second-line treatment for EGFR T790M-positive NSCLC

Recursion Pharmaceuticals completes series A funding round

Therapeutic potential of targeting of PLAUR/TLR4 interaction in TP53-positive cancers

Catabasis Pharmaceuticals completes target enrollment for part B of MoveDMD trial

TAK1 is a promising new target for osteoarthritis

FDA accepts IND application for ASN-003

Daiichi Sankyo enters collaboration with AgonOx to develop immuno-oncology target

EMA grants SME designation to Dipexium Pharmaceuticals

FDA grants breakthrough therapy designation to Actemra for giant cell arteritis

New BARDA contract supports advanced development of V-920 Ebola Zaire vaccine

Ocular Therapeutix initiates first phase III trial of OTX-TP for glaucoma and ocular hypertension

Merck & Co. patents PDE2A inhibitors

Heptares Therapeutics discloses muscarinic M1 and M4 receptor agonists

Bristol-Myers Squibb describes TNF-alpha antagonists

Turing and Washington University partner on toxoplasmosis

GlaxoSmithKline presents bromodomain inhibitors

The Vanderbilt University reports mGlu2 receptor negative allosteric modulators

Altor and NantKwest sign cancer immunotherapy codevelopment agreement

twoXAR collaborates with Mount Sinai researchers in diabetic nephropathy

Bone Therapeutics reports promising data on Allob from phase IIa spinal fusion trial

Riptide Bioscience executes CRDA with NCI

Slit3 shows potential as a therapeutic target in metabolic bone diseases

Dimerix reports positive safety data for phase II trial of DMX-200

Lrp6 may be a new PTH-activated aNAC target gene

FDA grants orphan drug designation to AbbVie's atrasentan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...